Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.
Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.
Abstract: The use of glycolipids, in particular galactosylceramide, glucosylceramide and lactosylceramide, and specific catchers therefor (antibodies or lectins), in particular monoclonal antibodies, for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications in an individual and for use in the production of pharmaceutical preparations for treatment of said conditions is disclosed.